Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Current Deferred Revenue (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Current Deferred Revenue for 4 consecutive years, with $5.5 million as the latest value for Q3 2025.

  • Quarterly Current Deferred Revenue fell 53.52% to $5.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Sep 2025, down 53.52% year-over-year, with the annual reading at $9.8 million for FY2024, 46.02% down from the prior year.
  • Current Deferred Revenue hit $5.5 million in Q3 2025 for Taysha Gene Therapies, roughly flat from $5.5 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $33.6 million in Q4 2022 to a low of $5.5 million in Q3 2025.
  • Historically, Current Deferred Revenue has averaged $15.7 million across 4 years, with a median of $14.1 million in 2024.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 32.9% in 2024 and later crashed 59.51% in 2025.
  • Year by year, Current Deferred Revenue stood at $33.6 million in 2022, then plummeted by 46.04% to $18.1 million in 2023, then crashed by 46.02% to $9.8 million in 2024, then crashed by 43.88% to $5.5 million in 2025.
  • Business Quant data shows Current Deferred Revenue for TSHA at $5.5 million in Q3 2025, $5.5 million in Q2 2025, and $7.5 million in Q1 2025.